Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P67
Within normal range
vs 2Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 16.12% |
| Q3 2025 | -21.98% |
| Q2 2025 | 1.98% |
| Q1 2025 | 5.36% |
| Q4 2024 | 33.79% |
| Q3 2024 | 23.12% |
| Q2 2024 | 1.58% |
| Q1 2024 | -2.92% |
| Q4 2023 | 23.28% |
| Q3 2023 | -31.30% |
| Q2 2023 | 160.46% |
| Q1 2023 | -8.14% |
| Q4 2022 | 0.00% |